CNS/Brain Cancer
From the Journals
First combo trial of mTOR/BRAF inhibition shows potential
A combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the BRAF inhibitor vemurafenib appears safe for patients with...
From the Journals
Nivolumab plus ipilimumab effective in melanoma brain metastases
Treatment with nivolumab plus ipilimumab resulted in clinically meaningful efficacy for melanoma patients with asymptomatic, previously untreated...
From the Journals
Adding checkpoint inhibitors to radiotherapy requires particular caution in this one scenario
Among scenarios where immune checkpoint inhibitors (ICIs) might be combined, particular caution is needed in the setting of brain metastases,...
From the Journals
Immunotherapies extend survival for melanoma patients with brain metastases
Patients with melanoma brain metastases receiving first-line checkpoint blockade immunotherapy had a 91% increase in 4-year survival.
From the Journals
Recombinant poliovirus appears safe, active as recurrent glioblastoma treatment
The survival data in a phase 1 study of 61 patients showed a plateau, with a 36-month survival rate of 21%, compared with 4% for a historical...
From the Journals
Screening for brain mets could improve quality of life for some with breast cancer
Compared with NSCLC patients, breast cancer patients presented with larger and more numerous brain mets, resulting in more invasive treatments,...
Conference Coverage
cfDNA reveals targetable mutations in pediatric neuroblastoma, sarcoma
PITTSBURGH – ‘Liquid biopsy’ of patients with genetically profiled tumors showed potentially actionable somatic mutations and copy number...
Conference Coverage
Surgery indicates higher survival with adrenal cortical carcinoma
CHICAGO
Conference Coverage
Study: Test for PD-L1 amplification in solid tumors
PD-L1 amplification is rare in solid tumors, but responses to PD-1/PD-L1 blockade seen in patients with the amplification warrant testing for it...
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
News
FDA approves biosimilar to bevacizumab
Bevacizumab-awwb is approved for the treatment of adults with certain colorectal, lung, brain, kidney, and cervical cancers.